Shares of NeoGenomics, Inc. (NASDAQ:NEO – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average 1-year price […]

Related Keywords

Texas , United States , Canada , United Kingdom , William Blair , Piper Sandler , Nasdaq , Clinical Services , Pricet Rowe Associates Inc , Needham Company , Texas Capital Bank Wealth Management Services Inc , Bellevue Group , Canada Life Assurance , Neogenomics Inc , Gabelli Funds , Get Free Report , Genomics Trading Down , Get Free , Advanced Diagnostics , Neogenomics Daily ,